Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2261

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target ; volume:18 ; number:1 ; day:20 ; month:10 ; year:2018 ; pages:1-12 ; date:12.2018
BMC cardiovascular disorders ; 18, Heft 1 (20.10.2018), 1-12, 12.2018

Creator: Heliste, Juho

Contributor: Jokilammi, Anne
Paatero, Ilkka
Chakroborty, Deepankar
Stark, Christoffer
Savunen, Timo
Laaksonen, Maria
Elenius, Klaus
SpringerLink (Online service)

DOI: 10.1186/s12872-018-0933-y

URN: urn:nbn:de:101:1-2018112113320200455083

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:51 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Heliste, Juho
Jokilammi, Anne
Paatero, Ilkka
Chakroborty, Deepankar
Stark, Christoffer
Savunen, Timo
Laaksonen, Maria
Elenius, Klaus
SpringerLink (Online service)

Other Objects (12)

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD

Editorial: Targeting bruton tyrosine kinase

Proteomic profiling identifies novel inflammation-related plasma proteins associated with ischemic stroke outcome

Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations

Newer Tyrosine Kinase Inhibitors for CML

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling

Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials

Second-generation inhibitors of Bruton tyrosine kinase

Bcr-Abl tyrosine kinase inhibitors- current status

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD

Editorial: Targeting bruton tyrosine kinase

Proteomic profiling identifies novel inflammation-related plasma proteins associated with ischemic stroke outcome

Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations

Newer Tyrosine Kinase Inhibitors for CML

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling

Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials

Second-generation inhibitors of Bruton tyrosine kinase

Bcr-Abl tyrosine kinase inhibitors- current status

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD

Editorial: Targeting bruton tyrosine kinase

Proteomic profiling identifies novel inflammation-related plasma proteins associated with ischemic stroke outcome

Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations

Newer Tyrosine Kinase Inhibitors for CML

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling

Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials

Second-generation inhibitors of Bruton tyrosine kinase

Bcr-Abl tyrosine kinase inhibitors- current status

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD

Editorial: Targeting bruton tyrosine kinase

Proteomic profiling identifies novel inflammation-related plasma proteins associated with ischemic stroke outcome

Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations

Newer Tyrosine Kinase Inhibitors for CML

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling

Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials

Second-generation inhibitors of Bruton tyrosine kinase

Bcr-Abl tyrosine kinase inhibitors- current status

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD

Editorial: Targeting bruton tyrosine kinase

Proteomic profiling identifies novel inflammation-related plasma proteins associated with ischemic stroke outcome

Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations

Newer Tyrosine Kinase Inhibitors for CML

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling

Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials

Second-generation inhibitors of Bruton tyrosine kinase

Bcr-Abl tyrosine kinase inhibitors- current status

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD

Editorial: Targeting bruton tyrosine kinase

Proteomic profiling identifies novel inflammation-related plasma proteins associated with ischemic stroke outcome

Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations

Newer Tyrosine Kinase Inhibitors for CML

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling

Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials

Second-generation inhibitors of Bruton tyrosine kinase

Bcr-Abl tyrosine kinase inhibitors- current status

Related objects

Reset password